SmithKline-Beecham's Coreg reduces CHF mortality by 67% in trial -- AHA meeting.
Executive Summary
SMITHKLINE BEECHAM COREG (CARVEDILOL) DECREASES MORTALITY BY 67% in patients with mild to severe congestive heart failure, according to data from a multi-center trial presented at the American Heart Association's 68th Scientific Sessions in Anaheim, California Nov. 13. The mortality rate in the carvedilol arm was 3% (21/696) compared to 7.8% (31/398) in placebo. The risk reduction was similar across CHF severity, Packer reported. Risk reduction among Class II patients using carvedilol was 68% (2.4% mortality in carvedilol vs. 5.8% mortality in placebo) while risk reduction in Class III-IV was 67% (3.7% vs. 10%).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth